CHDI, Inc.

12 articles about CHDI, Inc.

• EVOTEC CONFIRM CLOSING OF TRANSACTION WITH SANOFI TO ACCELERATE INFECTIOUS DISEASE RESEARCH AND DEVELOPMENT

  7/3/2018

  Evotec AG today announced that the strategic transaction to integrate Sanofi's infectious disease unit including licensing-in the majority of Sanofi's infectious disease research portfolio, has been successfully closed with effect from 01 July 2018.

• Evotec and Celgene Enter into Strategic Oncology Partnership

  5/22/2018

  Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation ("Celgene") have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.

• Alnylam Pharmaceuticals, Medtronic, Inc. & CHDI, Inc. Form RNAi Delivery Collaboration

  11/8/2010

• Albany Molecular Research, Inc. Commences Drug Discovery Collaboration with CHDI, Inc.

  4/29/2009

• Stem Cell Sciences plc Enters into Services Agreement with Huntingdon's Disease Research Group, CHDI Foundation Inc.

  11/10/2008

• Galapagos NV and CHDI, Inc. Enter New Collaboration Agreements

  10/29/2008

• Vertex Pharmaceuticals Incorporated Establishes Early-Stage Huntington’s Disease Research Collaboration with CHDI, Inc.

  6/17/2008

• Huntington Disease Foundation to Assess Six of CHDI, Inc.'s Drugs for Potential to Delay or Slow Progression of the Disease

  1/24/2008

• Serenex and CHDI, Inc. Form Agreement to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Huntington's Disease

  1/17/2008

• CHDI, Inc. Selects Evotec As Strategic Drug Discovery Partner In The Search For Huntington Disease Treatments

  8/10/2006

• CHDI, Inc. And Edison Pharmaceuticals, Inc. Enter Collaborative Agreement; Development Of Therapeutics Targeting Huntington's Disease

  8/1/2006

• Cellumen, Inc. And CHDI, Inc. Announce An Agreement To Create A Systems Cell Biology Profile Of Huntington's Disease

  2/23/2006